GENMAB A/S (GE9.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:GE9 - DK0010272202 - Common Stock
293.9 EUR
+3.2 (+1.1%)
Overall GE9 gets a fundamental rating of 7 out of 10. We evaluated GE9 against 86 industry peers in the Biotechnology industry. GE9 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GE9 is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make GE9 suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- GE9 had positive earnings in the past year.
- In the past year GE9 had a positive cash flow from operations.
- GE9 had positive earnings in each of the past 5 years.
- In the past 5 years GE9 always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of GE9 (21.10%) is better than 93.98% of its industry peers.
- The Return On Equity of GE9 (25.76%) is better than 93.98% of its industry peers.
- With an excellent Return On Invested Capital value of 17.11%, GE9 belongs to the best of the industry, outperforming 93.98% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for GE9 is above the industry average of 11.58%.
- The last Return On Invested Capital (17.11%) for GE9 is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- GE9 has a Profit Margin of 41.35%. This is amongst the best in the industry. GE9 outperforms 92.77% of its industry peers.
- In the last couple of years the Profit Margin of GE9 has declined.
- Looking at the Operating Margin, with a value of 36.85%, GE9 belongs to the top of the industry, outperforming 92.77% of the companies in the same industry.
- GE9's Operating Margin has declined in the last couple of years.
- GE9 has a Gross Margin of 94.27%. This is amongst the best in the industry. GE9 outperforms 90.36% of its industry peers.
- GE9's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GE9 is creating value.
- Compared to 1 year ago, GE9 has less shares outstanding
- GE9 has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, GE9 has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 101.93 indicates that GE9 is not in any danger for bankruptcy at the moment.
- GE9 has a better Altman-Z score (101.93) than 100.00% of its industry peers.
- GE9 has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.12, GE9 belongs to the top of the industry, outperforming 93.98% of the companies in the same industry.
- GE9 has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.02, GE9 is in the better half of the industry, outperforming 72.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 101.93 |
ROIC/WACC2.44
WACC7.01%
2.3 Liquidity
- A Current Ratio of 6.03 indicates that GE9 has no problem at all paying its short term obligations.
- The Current ratio of GE9 (6.03) is better than 86.75% of its industry peers.
- A Quick Ratio of 6.01 indicates that GE9 has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 6.01, GE9 belongs to the top of the industry, outperforming 86.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 125.90% over the past year.
- Measured over the past years, GE9 shows a very strong growth in Earnings Per Share. The EPS has been growing by 28.38% on average per year.
- The Revenue has grown by 24.66% in the past year. This is a very strong growth!
- Measured over the past years, GE9 shows a very strong growth in Revenue. The Revenue has been growing by 31.16% on average per year.
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%25.21%
3.2 Future
- GE9 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.30% yearly.
- The Revenue is expected to grow by 13.38% on average over the next years. This is quite good.
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.3%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 14.56, which indicates a correct valuation of GE9.
- Based on the Price/Earnings ratio, GE9 is valued cheaper than 92.77% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, GE9 is valued a bit cheaper.
- Based on the Price/Forward Earnings ratio of 19.51, the valuation of GE9 can be described as rather expensive.
- GE9's Price/Forward Earnings ratio is rather cheap when compared to the industry. GE9 is cheaper than 85.54% of the companies in the same industry.
- GE9's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.56 | ||
| Fwd PE | 19.51 |
4.2 Price Multiples
- 69.88% of the companies in the same industry are more expensive than GE9, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, GE9 is valued a bit cheaper than the industry average as 78.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 174.74 | ||
| EV/EBITDA | 148.12 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of GE9 may justify a higher PE ratio.
PEG (NY)5.17
PEG (5Y)0.51
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
5. Dividend
5.1 Amount
- No dividends for GE9!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:GE9 (1/16/2026, 7:00:00 PM)
293.9
+3.2 (+1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap181.04B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts71.85
Price Target290.15 (-1.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.84%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)0.66%
Revenue beat(16)10
Avg Revenue beat(16)2.34%
PT rev (1m)-0.12%
PT rev (3m)N/A
EPS NQ rev (1m)0.82%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.04%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.56 | ||
| Fwd PE | 19.51 | ||
| P/S | 58.7 | ||
| P/FCF | 174.74 | ||
| P/OCF | 164.99 | ||
| P/B | 36.57 | ||
| P/tB | 57.65 | ||
| EV/EBITDA | 148.12 |
EPS(TTM)20.19
EY6.87%
EPS(NY)15.06
Fwd EY5.12%
FCF(TTM)1.68
FCFY0.57%
OCF(TTM)1.78
OCFY0.61%
SpS5.01
BVpS8.04
TBVpS5.1
PEG (NY)5.17
PEG (5Y)0.51
Graham Number60.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 101.93 |
F-Score7
WACC7.01%
ROIC/WACC2.44
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.3%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%25.21%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S / GE9.DE FAQ
Can you provide the ChartMill fundamental rating for GENMAB A/S?
ChartMill assigns a fundamental rating of 7 / 10 to GE9.DE.
Can you provide the valuation status for GENMAB A/S?
ChartMill assigns a valuation rating of 5 / 10 to GENMAB A/S (GE9.DE). This can be considered as Fairly Valued.
How profitable is GENMAB A/S (GE9.DE) stock?
GENMAB A/S (GE9.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of GENMAB A/S (GE9.DE) stock?
The Price/Earnings (PE) ratio for GENMAB A/S (GE9.DE) is 14.56 and the Price/Book (PB) ratio is 36.57.
What is the expected EPS growth for GENMAB A/S (GE9.DE) stock?
The Earnings per Share (EPS) of GENMAB A/S (GE9.DE) is expected to grow by 2.82% in the next year.